Paratek Pharmaceuticals Inc. (PRTK) Share Price Today, Stock Analysis, Annual Report | Value Research Paratek Pharmaceuticals Inc. (PRTK) - Get live share price today, stock analysis, price valuation, performance, fundamentals, market cap, share holding, financial report of US stocks.

Paratek Pharmaceuticals Inc. (PRTK)

Download Stock Report

NASDAQ: PRTK

  • Price Change
  • Market Capitalisation market-capitalisation-info $128 Mln

  • 12 Month Earnings monthly-earning $-63 Mln
  • Price to Earnings price-to-earning --

Paratek Pharmaceuticals Inc. (PRTK) Share Price

$2.23

As on 21-Sep-2023 09:30 EDT

$0.000.00%

  • Prev Close info

    $2.23

  • Day's Openinfo

    $2.23

  • Today's Highinfo

    $2.23

  • Today's Lowinfo

    $2.23

  • Today's Volumeinfo

    --

Please wait...

Paratek Pharmaceuticals Inc. (PRTK) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Paratek Pharmaceuticals (PRTK)
19.25 0.90 1.83 -7.08 -30.66 -24.76 -21.58
S&P BSE Sensex*
8.49 1.22 3.91 11.02 20.17 12.37 12.54
S&P Small-Cap 600#
-0.96 -4.96 -1.70 6.06 11.70 1.31 6.60
As on 21-Sep-2023  |  *As on 22-Sep-2023  |  #As on 24-Sep-2023
2022
2021
2020
2019
2018
2017
2016
Paratek Pharmaceuticals (PRTK)
-58.35 -28.27 55.33 -21.44 -71.14 16.23 -18.82
S&P Small-Cap 600
-17.42 25.27 9.57 20.86 -9.70 11.73 24.74
S&P BSE Sensex
4.44 21.99 15.75 14.38 5.87 27.91 1.95

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Paratek Pharmaceuticals Inc. (PRTK) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Paratek Pharmaceuticals Inc. (PRTK)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Exec. Chairman

        Mr. Michael F. Bigham CPA, CPA, M.B.A., MBA

        CEO & Director

        Dr. Evan Loh FACC, FAHA, M.D.

        Headquarters

        Boston, MA

        FAQs for Paratek Pharmaceuticals Inc. (PRTK)

        The total asset value of Paratek Pharmaceuticals Inc. (PRTK) stood at $ 348 Mln as on 30-Jun-23

        The share price of Paratek Pharmaceuticals Inc. (PRTK) is $2.230000 (NASDAQ) as of 21-Sep-2023 09:30 EDT. Paratek Pharmaceuticals Inc. (PRTK) has given a return of -30.66% in the last 3 years.

        Paratek Pharmaceuticals Inc. (PRTK) has a market capitalisation of $ 128 Mln as on 21-Sep-2023. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Paratek Pharmaceuticals Inc. (PRTK) is 0.00 times as on 21-Sep-2023, a -1% premium to its peers’ median range of 2.54 times.

        Since, TTM earnings of Paratek Pharmaceuticals Inc. (PRTK) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Paratek Pharmaceuticals Inc. (PRTK) and enter the required number of quantities and click on buy to purchase the shares of Paratek Pharmaceuticals Inc. (PRTK).

        Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.

        The CEO & director of Mr. Michael F. Bigham CPA, CPA, M.B.A., MBA. is Paratek Pharmaceuticals Inc. (PRTK), and CFO & Sr. VP is Dr. Evan Loh FACC, FAHA, M.D..

        The promoters of Paratek Pharmaceuticals Inc. (PRTK) have pledged 0% of the total equity as on Jun-23.

        Paratek Pharmaceuticals Inc. (PRTK) Ratios
        Return on equity(%)
        --
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        -0.47
        Dividend yield(%)
        0

        No, TTM profit after tax of Paratek Pharmaceuticals Inc. (PRTK) was $-63 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $127.83 Mln
        • Revenue (TTM)revenue-information $167.74 Mln
        • Earnings (TTM) earning-information $-62.73 Mln
        • Cash date-information $42.69 Mln
        • Total Debt info $259.76 Mln
        • Insider's Holding 11.70%
        • Liquidity liquidity High
        • 52 Week range week-range $1.29 - 3.65
        • Shares outstanding share-outstanding 57,322,400
        • 10 Years Aggregate:

          CFO: $-693.77 Mln

          EBITDA: $-660.83 Mln

          Net Profit: $-796.90 Mln

        About The Company

        • IPO Date 11-May-2006
        • Exec. Chairman Mr. Michael F. Bigham CPA, CPA, M.B.A., MBA
        • CEO & Director Dr. Evan Loh FACC, FAHA, M.D.
        • Listing key-listing NASDAQ: PRTK
        • Country United States
        • Headquarters headquarters Boston, MA
        • Website website https://paratekpharma.com
        • Business

          Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military...  use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.  Read more

        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free
        demystifying-mutual-fund

        What can Value Research do for you?

        solidify-your-fundamentals
        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        track-all-your-investments
        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        get-guidance-from-our-experts
        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        get-access-to-exclusive-analytics
        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.

        share-fund-plan-icon